Gerresheimer Küssnacht AG on course for growth
Expansion of medical plastic systems production
A new ISO class 8 clean room has been built for the production and assembly of auto-injection systems and equipped with stateof- the-art injection molding machines, robots and highly automated assembly lines. In the wake of the new expansion measures, new jobs were created and the company is inviting applicants with suitable qualifications.
After completion of the expansion measures, the Küssnacht site will have a production area with a total of more than 3,700 sqm, 2,900 sqm of which will be set aside for clean room production to ISO class 8 (100,000) and 800 sqm will be designated as controlled areas to ISO class 9. The facility will be equipped to cover the entire production chain, from manufacturing, postproduction finishing right throught to assembly, testing and packaging. The main focus of production operations at Küssnacht will be on the large-scale production of top-quality pharmaceutical products such as inhalers and auto-injection systems as well as products for laboratory and molecular diagnostics with an output in the multi-digit million range. The highly automated lines with a total of forty injection molding machines and fifteen complex assembly stations will run 24/7. The production site is certified to DIN EN ISO 9001:2008 and DIN EN ISO 13485:2003+AC2009 and passed an FDA inspection of the production of a medical product with direct blood contact without any observations.
Gerresheimer is a leading specialist for the production of premiumquality glass and plastic products for the international pharmaceutical and healthcare industry. We offer a wide range of products and services, from pharmaceutical vials right through to complex drug delivery systems such as syringe systems, insulin pens and inhalers for reliable and safe drug dispensing and application. Together with our partners, we develop concepts that set new standards and serve as a model for the entire industry.
With more than 10,000 employees and forty-seven production sites in Europe, the US, South America and Asia, our group of companies posts sales of about EUR 1bn. The systematic consolidation of our strong market position is based on top-rate technology, impressive innovations and strategic investments.